WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011017350) COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/017350    International Application No.:    PCT/US2010/044284
Publication Date: 10.02.2011 International Filing Date: 03.08.2010
IPC:
C07D 261/14 (2006.01), C07D 413/04 (2006.01), A61K 31/42 (2006.01), A61K 31/4427 (2006.01), A61P 11/06 (2006.01), A61P 35/00 (2006.01)
Applicants: AMIRA PHARMACEUTICALS, INC. [US/US]; 9535 Waples Street Suite 100 San Diego, CA 92121 (US) (For All Designated States Except US).
HUTCHINSON, John, Howard [US/US]; (US) (For US Only).
SEIDERS, Thomas, Jon [US/US]; (US) (For US Only).
WANG, Bowei [US/US]; (US) (For US Only)
Inventors: HUTCHINSON, John, Howard; (US).
SEIDERS, Thomas, Jon; (US).
WANG, Bowei; (US)
Agent: WILSON SONSINI GOODRICH & ROSATI; 650 Page Mill Road Palo Alto, CA 94304 (US)
Priority Data:
61/231,282 04.08.2009 US
Title (EN) COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
(FR) COMPOSÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'ACIDE LYSOPHOSPHATIDIQUE
Abstract: front page image
(EN)Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
(FR)La présente invention concerne des composés qui sont des antagonistes du ou des récepteurs lysophosphatidiques. L'invention porte en outre sur des compositions pharmaceutiques et des médicaments qui comprennent les composés ci-décrits, ainsi que sur des procédés d'utilisation de ces antagonistes, seuls ou combinés avec d'autres composés, dans le traitement de pathologies ou de maladies dépendantes du LPA ou médiées par le LPA.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)